SCOTTSDALE, Ariz., March 13, 2006 (PRIMEZONE) -- Medicis (NYSE:MRX - News) today announced the signing of an agreement whereby subject only to the closing of Allergan Inc.'s tender offer for Inamed Corp. shares (``Allergan Tender Offer'') Ipsen (Eurolist by Euronext(TM):IPN) will grant Aesthetica Ltd., a wholly owned subsidiary of Medicis (``Medicis''), rights to develop, distribute and commercialize Ipsen's botulinum toxin product in the United States, Canada and Japan for aesthetic use by physicians. The product is commonly referred to as Reloxin(R) in the U.S. aesthetic market and Dysport(R) for medical and aesthetic markets outside the U.S. The product is not currently approved for use in the U.S. Ipsen will recover its rights to Reloxin(R) at the time of the closing of the Allergan Tender Offer.
